Rhumbline Advisers Karyopharm Therapeutics Inc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024
SELL
$0.87 - $1.58 $111,009 - $201,603
-127,597 Reduced 88.59%
16,431 $14,000
Q1 2024

May 09, 2024
BUY
$0.72 - $1.66 $4,263 - $9,828
5,921 Added 4.29%
144,028 $217,000
Q4 2023

Feb 08, 2024
SELL
$0.68 - $1.31 $34 - $65
-50 Reduced 0.04%
138,107 $118,000
Q3 2023

Nov 09, 2023
BUY
$1.14 - $1.81 $4,072 - $6,465
3,572 Added 2.65%
138,157 $185,000
Q2 2023

Aug 08, 2023
BUY
$1.79 - $4.59 $54,226 - $139,049
30,294 Added 29.05%
134,585 $240,000
Q1 2023

May 11, 2023
BUY
$2.84 - $3.92 $15,764 - $21,759
5,551 Added 5.62%
104,291 $406,000
Q4 2022

Feb 14, 2023
SELL
$2.48 - $5.93 $2,484 - $5,941
-1,002 Reduced 1.0%
98,740 $336,000
Q3 2022

Nov 10, 2022
BUY
$4.08 - $5.82 $33,912 - $48,375
8,312 Added 9.09%
99,742 $545,000
Q2 2022

Aug 11, 2022
BUY
$4.15 - $8.37 $51,074 - $103,009
12,307 Added 15.55%
91,430 $412,000
Q1 2022

May 12, 2022
SELL
$5.91 - $14.38 $92,119 - $224,141
-15,587 Reduced 16.46%
79,123 $583,000
Q4 2021

Feb 10, 2022
SELL
$5.21 - $8.61 $7,716 - $12,751
-1,481 Reduced 1.54%
94,710 $609,000
Q3 2021

Nov 12, 2021
SELL
$4.45 - $10.63 $131,257 - $313,542
-29,496 Reduced 23.47%
96,191 $560,000
Q2 2021

Aug 05, 2021
BUY
$8.11 - $11.11 $38,603 - $52,883
4,760 Added 3.94%
125,687 $1.3 Million
Q1 2021

May 06, 2021
SELL
$9.85 - $17.69 $37,252 - $66,903
-3,782 Reduced 3.03%
120,927 $1.27 Million
Q4 2020

Feb 10, 2021
BUY
$14.15 - $17.19 $42,464 - $51,587
3,001 Added 2.47%
124,709 $1.93 Million
Q3 2020

Nov 12, 2020
SELL
$14.14 - $19.71 $263,682 - $367,552
-18,648 Reduced 13.29%
121,708 $1.78 Million
Q2 2020

Aug 13, 2020
BUY
$16.6 - $25.25 $233,711 - $355,494
14,079 Added 11.15%
140,356 $2.66 Million
Q1 2020

May 06, 2020
BUY
$14.38 - $27.72 $36,740 - $70,824
2,555 Added 2.07%
126,277 $2.43 Million
Q4 2019

Feb 05, 2020
BUY
$9.23 - $19.67 $72,169 - $153,799
7,819 Added 6.75%
123,722 $2.37 Million
Q3 2019

Oct 23, 2019
BUY
$5.66 - $11.85 $2,462 - $5,154
435 Added 0.38%
115,903 $1.12 Million
Q2 2019

Aug 14, 2019
SELL
$4.32 - $6.43 $73,794 - $109,837
-17,082 Reduced 12.89%
115,468 $692,000
Q1 2019

May 01, 2019
BUY
$4.12 - $10.25 $159,571 - $396,992
38,731 Added 41.28%
132,550 $774,000
Q4 2018

Jan 31, 2019
BUY
$8.2 - $16.95 $419,536 - $867,212
51,163 Added 119.94%
93,819 $879,000
Q3 2018

Nov 07, 2018
SELL
$17.03 - $21.18 $45,555 - $56,656
-2,675 Reduced 5.9%
42,656 $726,000
Q2 2018

Aug 06, 2018
BUY
$12.0 - $19.88 $141,252 - $234,007
11,771 Added 35.07%
45,331 $770,000
Q1 2018

May 02, 2018
BUY
$9.92 - $17.25 $9,672 - $16,818
975 Added 2.99%
33,560 $450,000
Q4 2017

Feb 09, 2018
SELL
$9.15 - $11.99 $389,991 - $511,037
-42,622 Reduced 56.67%
32,585 $313,000
Q3 2017

Nov 06, 2017
BUY
$8.15 - $11.16 $612,937 - $839,310
75,207
75,207 $826,000

Others Institutions Holding KPTI

# of Institutions
98
Shares Held
57.6M
Call Options Held
258K
Put Options Held
81.2K
View Full List

About Karyopharm Therapeutics Inc.

KPTI Quotes by TradingView
  • Ticker KPTI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 79,806,600
  • Market Cap $55.9M
  • Description
  • Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...
More about KPTI
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email